Publications List

Including Posters, Presentations, Abstracts, and Webcasts

April 2019


2017


Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. *J Clin Epidemiol.* 2015 Jan;68(1):102-107.


Ryan CJ, Buettner A, Britton SL, Lankford M, Neely DB, Green MR. Prospective evaluation of prescribing preferences (PPrefs) of U.S.-based oncologists in the postdocetaxel mCRPC patient (Pt). *J Clin Oncol.* 32, 2014 (suppl; abstr e16011) [published online].

Faria C, Jackson J, Lunacsek O, Hennenfent KL. Time to progression and time to treatment failure in patients with triple-negative metastatic breast cancer receiving eribulin mesylate in a community oncology setting. *J Clin Oncol.* 2014;32(suppl; abstr e12039) [published online].


### 2008–2013


Howel P, Burich M. Biosimilars: an uncertain path to promise. As the costs of drugs rise, will biosimilars fulfill their promise of affordability? Pharmpro. 2012 Oct;36-37.


**2002–2007**


Eaddy MT, Druss BG, Sarnes MW, Regan TS, Frankum (Happe) LE. Relationship of total health care charges to SSRI utilization patterns including the length of antidepressant therapy. *J Manag Care Pharm.* 2005;11(2):145-150.


1998–2001


1991–1997


2019

Kudrow D, Sagar M, Bensimon L, Lokhandwala T, Yue B, Silberstein S. Comorbidity, treatment patterns, and economic burden of primary headache disorders: an administrative claims data analysis. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.


Raju AD, Pimple P, Stafkey-Mailey D, Farrelly EM, Shetty S. A real-world claims analysis of costs among patients with type 2 diabetes mellitus and cardiovascular disease receiving empagliflozin or other antihyperglycemic agents. Poster presented at: American Heart Association Quality of Care and Outcomes Research 2019 Scientific Sessions; April 5-6, 2019; Arlington, VA.

Moradi A, Spargo A, Mezzio D, Kaufman S. A discrete choice experiment and cost-minimization analysis of payer preferences for innovative payment schemes aimed at financing high-cost, potentially curative therapies. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

Jang SR, Danavar A, Choi M, Kaufman S, McCart M. Payer perceptions on access to breastfeeding support in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; March 25-28, 2019; San Diego, CA.

2018


Bloudek L, Brokars J, Campbell D, Makenbaeva D. Realized and projected cost savings from the introduction of generic imatinib, with minimal additional savings to payers through formulary management. Poster presented at: 60th American Society of Hematology (ASH) Annual Meeting & Exposition; December 1-4, 2018; San Diego, CA.

Gittings K, Moradi A, Begovic E, Sarnes E, Mody L. A systematic literature review of health outcomes associated with plant-based diets. Poster presented at: Academy of Managed Care Nexus Annual Meeting; October 22-25, 2018; Orlando, FL.

Gillard KK, Moradi A, Bloudek L. Budget impact analysis of glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis (PAHH). Poster presented at: Academy of Managed Care Nexus Annual Meeting; October 22-25, 2018; Orlando, FL.

Moradi A, Simmons D, Yun SA, Regan TS, Eaddy M. Comparing the ability of comorbidity and polypharmacy measures to predict payer healthcare expenditures: a literature review. Poster presented at: Academy of Managed Care Nexus Annual Meeting; October 22-25, 2018; Orlando, FL.

Wilson S, Frank T, Hilton P, Snow J, Shields S, Campbell C. Payer familiarity and perceptions with state legislative measures to control drug cost in the US. Poster presented at: Academy of Managed Care Nexus Annual Meeting; October 22-25, 2018; Orlando, FL.


Damen D, Templin C, Ulrich S, Kulp W. Implications of the fast-evolving therapeutic landscape on appropriate comparators in oncological AMNOG benefit assessments. Poster presented at: ISPOR Europe Annual Meeting; November 10-14, 2018; Barcelona, Spain.


safety, and impact of results on clinical management. Poster presented at: Annual Scientific Session of the American Society of Nuclear Cardiology (ASNC); September 6-9, 2018; San Francisco, CA.

Landsman-Blumberg P, Lokhandwala T, Le Lay A, Dean B, Stafkey-Mailey D. Standard propensity score weighting did not result in balanced cohorts, now what? Poster presented at: 34th International Conference on Pharmacoepidemiology; August 22-26, 2018; Prague, Czech Republic.


Kuchenbecker U, Massanari M, Mittendorf T, Werner I. Budget impact of using FeNO in the management of asthma patients in Germany. Poster presented at: European Academy of Allergy and Clinical Immunology (EAACI) Congress; May 26-30, 2018; Munich, Germany.

Shih HC, Forys A, Le J, Kugel M, Roberto P. Medicare Part D spending trends among enrollees in employer group waiver plans compared to non–low-income subsidy enrollees. Poster presented at: Annual Research Meeting; June 24-26, 2018; Seattle, WA.


Mezzio D. Assessing drug price changes over 1 year and their influence on budget impact. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.


Ruban C, Burgess SM. Development of a conceptual model and review of patient and observer-reported outcome measures in atopic dermatitis. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.
Gillard KK, Bloudek LM. Epidemiology of hyperhidrosis in the United States: a systematic literature review. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Clark RS, Gittings K, Campbell CM, Meyer KL. 2018 update of health technology assessment decisions across the globe: a focus on oncology. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Nguyen V, Kanaskar A, Migliaccio-Walle K, Shields K. Utilization and impact of value assessment frameworks on payer decisions regarding chimeric antigen receptor T-cell therapies. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Bozkaya D. Projected savings in direct and indirect costs due to reduced diabetes prevalence with vegetarian diets. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: ISPOR 23rd Annual International Meeting; May 19-23, 2018; Baltimore, MD.

Taylor A, Wissinger E, Cadarette S, Ruiz K, Akbari M. Adverse event (AE) profile of treatments used in steroid-refractory acute graft vs host disease (SR-aGvHD) in comparison to autoimmune disease indications: a literature review. Poster presented at: Blood and Marrow Transplant Tandem Meeting; February 21-25, 2018; Salt Lake City, UT.

Parcher B, Gabriel S, Ruiz K, Ariely R, Mosnaim G. Digital technology interventions and their outcomes in moderate to severe asthmatic patients: a targeted literature review. Poster presented at: AAAAI/WAO Joint Congress; March 2-5, 2018; Orlando, FL.


Gaiser A, Abdel-Sattar M, Shamseddine N, Shields S. Payer evaluation of organizational management approaches to limit opioid abuse and overdose deaths in the United States. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Mody LB, Boswell KA, Ren SP, Kaufman S, Hughes J, Sarnes EF. Payer perspective on the Academy of Managed Care Pharmacy (AMCP) Format Version 4.0 (v4.0) pre-approval dossier in a managed care network. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: Academy of Managed Care Pharmacy Annual Meeting; April 23-26, 2018; Boston, MA.

Carlton R, Regan T, Narayanan S. The economic impact of EMFLAZA® (deflazacort) for the treatment of Duchenne muscular dystrophy. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.

Mezzio D, Brown D. Assessing drug price changes over 1 year and their influence on budget impact. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.

Bozkaya D. Projected savings in direct and indirect costs due to reduced diabetes prevalence with vegetarian diets. Poster presented at: ISPOR 23rd Annual International Conference; May 19-23, 2018; Baltimore, MD.


2017


Lokhandwala T, Bhor M, Stafkey-Mailey D, Chen H, Elliott BM. Comparison of treatment characteristics between patients diagnosed with immune thrombocytopenia (ITP) and treated with thrombopoietin receptor agonists (TPO-RA). Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 2-6, 2017; Chicago, IL.


Chari A, Romanus D, Luptakova K, Raju A, Farrelly E, Cain LE, Blazer M, Skacel T, Hari P. Duration of therapy (DOT) and time to next therapy (TTNT) of bortezomib, carfilzomib, and ixazomib combinations with lenalidomide/dexamethasone (VRd, KRd, IRd) in patients with relapsed/refractory multiple myeloma (RRMM): early clinical practice experience in the United States vs clinical trial experience. Poster presented at: 59th Annual Meeting and Exposition of the American Society of Hematology (ASH); December 9-12, 2017; Atlanta, GA.


Agashe V, Duhig A, Floyd J, Maiese B, Slaff S. Quality of life (QoL), functional status (FS), and survival in triple negative breast cancer (TNBC): discordance of definitions between a targeted literature review and stakeholder interviews. Poster presented at: ISPOR’s 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.


Ruban C. Assessing the healthcare cost of diabetic non-small cell lung cancer patients compared to non-small cell lung cancer patients. Poster presented at: ISPOR’s 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.


McLeod K. Remote therapy management of patients on automated peritoneal dialysis demonstrates cost savings in Germany and Italy. Poster presented at: ISPOR’s 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.


O’Day K, Campbell D, Meyer K. When the outcome of an appraisal is not nice: a review of NICE appeals. Poster presented at: ISPOR’s 20th Annual European Congress; November 5-8, 2017; Glasgow, Scotland.


Stafkey-Mailey D, Wang W, Murty S, Shetty S. Validation of an algorithm to identify death in administrative claims data. Poster presented at: AMCP’s Nexus Meeting; October 16-19, 2017; Dallas, TX. **Gold Medal Winner.**


Kaufman S, Hughes J, Duhig A. The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey. Poster presented at: AMCP’s Nexus Meeting; October 16-19, 2017; Dallas, TX. **Silver Medal Winner.**


McLeod K, Duhig A, Ogbonnaya A, Quillon A, Yue B. Prospective study of real-world outcomes in the treatment of neurogenic orthostatic hypotension with droxidopa. Poster presented at: AMCP’s Nexus Meeting; October 16-19, 2017; Dallas, TX.

Moreland K, Kugel M, Liu T. Burden of post-operative nausea or vomiting associated with acute postoperative pain treatment. Poster presented at: AMCP’s Nexus Meeting; October 16-19, 2017; Dallas, TX.


Clark R, Campbell CM, Meyer KL. Results, rationales, and trends in health technology assessments for novel diabetes agents. Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.


Stafkey-Mailey D, Yue B. Treatment patterns among patients diagnosed with advanced melanoma in a commercially insured population. Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.


Farrelly E, Blazer M, Ogbonnaya A, Eaddy M. Beyond hypomethylating agents (HMAS): treatment of patients with higher-risk myelodysplastic syndromes (HR-MDS) after first-line therapy (1LT) using a United States (US) electronic medical record (EMR). Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

Liu T, Benjamin N, Popelar B. A1C levels and factors associated with glycemic control among patients with diabetes mellitus in the US. Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.


Ogbonnaya A, Lokhandwala T, Duhig A. Does the commercial availability of clobazam affect healthcare resource utilization and costs among patients with Lennox-Gastaut syndrome? Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.


Parcher B, Shamseddine N, Walters T, Campbell C. US payer assessment of late-stage clinical trials involving digital health technologies and pharmaceutical manufacturers. Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.

O’Day K, Brown D. Cohort analysis methods to estimate the budget impact of oncology treatments by line of therapy. Poster presented at: ISPOR’s 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.


Yue B, Lankford M, Landsman-Blumberg P. Estimating healthcare costs for advanced metastatic bladder cancer patients who are lost to follow-up: applications of the Kaplan-Meier sampling average (KMSA). Poster presented at: The American Society of Clinical Oncology (ASCO) 2017 Quality Care Symposium; March 3-4, 2017; Orlando, FL.


Romanus D, Raju A, Farrelly E, Noga S, Blazer M, Hari P. Treatment patterns and outcomes by line of therapy (LOT) in a large United States (US) cohort of transplant-ineligible patients with multiple myeloma in the era of novel agents. Poster presented at: The 16th International Myeloma Workshop; March 1-4, 2017; New Delhi, India.


2014–2016

Vegesna A, Panettieri RA, Gabriel S, Ruiz KM, Colby JA, Maiese BA, Corren J. Patient-reported outcomes (PROs) in patients receiving omalizumab: a systematic literature review. Poster presented at: American Academy of Allergy, Asthma & Immunology Annual Meeting; March 4-7, 2016; Los Angeles, CA.


Romanus D, Raju A, Seal B, Farrelly E, Yong C, Noga SJ, Jhaveri M, Labotka R, Blazer M, Hari P. The clinical course of relapsed or refractory multiple myeloma (RRMM) U.S. patients receiving two or more lines of therapy. Poster presented at: European Hematology Association 21st Congress; June 9-12, 2016; Copenhagen, Denmark.


Brown D, Lehnigk U, Karjalainen M, Locklear J. Patient and caregiver reported problems in the utilisation of epinephrine auto-injectors for management of severe allergic reactions. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting (FAAM); October 13-15, 2016; Rome, Italy.

Brown D, Lehnigk U, Karjalainen M, Locklear J. Weaknesses of treatment guidelines for the management of anaphylaxis and healthcare utilization following an anaphylaxis event. Poster presented at: 4th Food Allergy and Anaphylaxis Meeting (FAAM); October 13-15, 2016; Rome, Italy.

Maiese B, Cadarette S, Campbell D, Arvin-Berod C. Findings of a literature review in support of a patient count model (PCM) for hepatitis C virus (HCV) in the EU5. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Sarnes E, Shields K, Kaufman S, Meyer K. Global value dossiers (GVDs): how to ensure the value isn’t lost in translation. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.


Brown D. Retrospective database analysis on anaphylaxis and patient concordance in the United States. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Stafkey-Mailey D. Real-world treatment patterns and outcomes for patients with advanced soft tissue sarcoma receiving systemic therapy in the United Kingdom. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

O’Day K, Campbell D. Cost-utility analysis of exercise for the prevention of cancer. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

Stafkey-Mailey D. Advanced soft tissue sarcoma: systemic treatment patterns and survival in Germany. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.

O’Day K, Campbell D. Results from a model to forecast the current and future number of patients eligible for treatment of refractory advanced nonsmall cell lung cancer (NSCLC) in France, Germany, Italy and Spain. Poster presented at: ISPOR’s 19th Annual European Congress; October 29-November 2, 2016; Vienna, Austria.


Boswell K, Mody L, Sawchyn B, Sarnes E. Value, utility, and challenges with the Academy of Managed Care Pharmacy (AMCP) format dossier: implications of version 4.0 (v4.0). Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD. Gold Medal Winner.


Landsman-Blumberg P, Carroll C, Murty S, Slaff S. Patterns of antibiotic treatment failure in pediatric community-acquired bacterial pneumonia in the USA. Poster presented at: AMCP Nexus 2016; October 3-6, 2016; National Harbor, MD.


Eaddy M, Cross N, Hanna D. Predictors of low patient activation when initiating C1 esterase inhibitor therapy for hereditary angioedema. Poster presented at: ISPOR’s 21st Annual Meeting; May 21-25, 2016; Washington, DC.


Popelar B. Real-world treatment patterns and demographic, clinical, and economic characteristics of systemic lupus erythematosus (SLE) patients initiating repository corticotropin injection therapy. Poster presented at: AMCP’s 28th Annual Meeting & Expo; April 19-22, 2016; San Francisco, CA.

François C, Houle C, Duhig A. Development of a neurogenic orthostatic hypotension activities of daily living (NOH ADL) scale. Poster presented at: American Academy of Neurology (AAN 2016); April 15-21, 2016; Vancouver, BC.

Ng-Mak DS, O’Day K, Chuang CC, Friedman ML, Rajagopalan K, Loebel A. Cost savings associated with improved adherence among patients with schizophrenia using lurasidone. Poster presented at: American Psychiatric Association (APA) Annual Meeting; May 14-18, 2016; Atlanta, GA.


O’Day K, Campbell D. Cost-utility analysis of chocolate consumption for prevention of cardiometabolic disease. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Jacob C, Meise D, Mittendorf T, Braun S. The use of real world evidence to support market access of medical devices—implications for the German setting. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Haas J, Jacob C, Braun S. Comparative effectiveness of granulocyte colony-stimulating factors (G-CSF) for reducing incidence of febrile neutropenia (FN)-related hospitalization: a retrospective. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O’Day K, Campbell D. Patient count forecasts of advanced non-small cell lung cancer: results from the UK, Germany, France, Italy and Spain (EU-5). Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Borchert K, Haas J, Mittendorf T, Braun S. Real world evidence in oncology—status quo in Germany. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Altevers J, Borchert K, Mittendorf T, Braun S. Prevalence and incidence estimations in German AMNOG applications—the role of real-world evidence (RWE). Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Clark R, Meyer K, Bramley T. Trends in health technology assessment decisions across the globe: a focus on hepatitis C. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Prosser C, Landsman-Blumberg P, Braun S. Treatment costs and patterns in patients with multiple sclerosis treated with prolonged-release fampridine in Germany. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

Prosser C, Altevers J, Braun S. Incidence and prevalence estimations based on claims data—new methodological considerations. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

McLeod K. Use of simulation to assess the impact of a remote monitoring system. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.

O’Day K, Liu S, Bozkaya D. A method to evaluate uncertainty due to unknown parameter correlation in stochastic decision models. Poster presented at: ISPOR’s 18th Annual European Congress; November 7-11, 2015; Milan, Italy.


Carlton R, Campbell C, Raju A, Eaddy M. Expected costs and projected annual budget impact of treatment of varicose veins with polidocanol endovenous microfoam 1%. Poster presented at: AMCP Nexus 2015; October 26-29, 2015; Orlando, FL.


Morland K, Carroll C. The importance of anchor based minimal clinically important difference (MCID) to health technology assessment of established intranasal allergic rhinitis treatments. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Popelar B, Walters T, Houle C, Duhig A. Use of work productivity endpoints in clinical studies: a review by disease state and measurement type. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

O’Day K, Campbell D. The expanded number needed to treat: applying the concept of NNT to continuous health economic outcomes. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Altevers J, Borchert K, Mittendorf T, Braun S. Use of real world evidence in German AMNOG applications. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.


Ogbonnaya A, Kish J, Eaddy M. Rate of adverse event-related treatment changes and healthcare costs associated with topical rosacea treatment. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.

Kish J, Eaddy M. Patterns of care in the workup and management of nonmetastatic and metastatic colorectal cancer. Poster presented at: ISPOR 20th Annual International Meeting; May 16-20, 2015; Philadelphia, PA.


Raju A, D’Souza A. Hypoglycemia rates and healthcare costs in patients with type 2 diabetes mellitus (T2DM) treated with 2nd line linagliptin or sulfonylurea after metformin. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Abdel-Sattar M, Denno M. Clinical pharmacy medication therapy management to improve real-world adherence to novel oral anticoagulants: results of a retrospective descriptive study. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Bloudek L, Eaddy M. Estimating cost per month of progression free survival (PFS) from a payer perspective: comparing commonly used treatment regimens for previously treated, i.e., relapsed and/or refractory multiple myeloma (RRMM). Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Allen L, Denno M, Jackson J. Trends in medication adherence: the payer perspective. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Denno M, Klein C, Lennert B. Analyzing the burden of hepatitis C using an outcomes evaluation tool within an integrated delivery network. Poster presented at: AMCP 27th Annual Meeting & Expo; April 7-10, 2015; San Diego, CA.

Gueron B, Kish J, O’Day K, Martel MJ, Manley Daumont M. Patient count projections for advanced melanoma by line of therapy and other clinical characteristics in EU countries: results from the UK, Germany, France, Italy, and Spain (EU-5). Poster presented at: ISPOR 17th Annual European Congress; November 8-12, 2014; Amsterdam, The Netherlands.


Denno M, Klein C, Campbell C. Evaluation of outcomes in patients with overactive bladder within an integrated healthcare delivery system using a treatment patterns analyzer. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA.


O’Day K, Meyer K. Budget impact model of eslicarbazepine acetate for refractory partial-onset epilepsy in a US health insurance plan. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA.
Bozkaya D, Migliaccio K, Bramley T. Evaluation of patient and financial outcomes associated with advanced infertility treatment options. Poster presented at: AMCP Nexus 2014; October 8-9, 2014; Boston, MA.


Faria C, Knoth R, Jackson J, Lunacsek O, Hennenfent K. The impact of anthracycline on progression-free survival and time-to-treatment failure in patients with metastatic breast cancer receiving eribulin mesylate in a community oncology setting. Poster presented at: Association for Value-Based Cancer Care 4th Annual Conference; May 6-9, 2014; Los Angeles, CA.


Zagadailov E, Carlton R, Bramley T. Budget impact of phentermine and topiramate extended-release (PHEN/TPM ER) in overweight and obese patients with comorbid prediabetes or type 2 diabetes mellitus (T2DM). Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting: Palais des Congrès de Montréal; May 31–June 4, 2014; Montréal, QC, Canada.


Rodby R, Umanath K, Niecestro R, Jackson J, Dwyer J, Lewis J. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Poster presented at: National Kidney Foundation Spring Clinical Meeting; April 22, 2014; Las Vegas, NV.

Lunacsek O, Bramley T. The economic burden of end-of-life care in metastatic breast cancer. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

O’Day K, Meyer K. Subcutaneous peginterferon beta-1a reduces relapse-associated costs in patients with relapsing-remitting multiple sclerosis. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Denno M, Popelar B, Jackson J, Lennert B. Managed care perceptions and utilization of outcomes analyzers in the United States. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Denno M, Jackson, J. Payers perspective on the future of genetic testing and personalized medicine. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.
Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Payer familiarity with oncology biomarkers, their companion diagnostics, and specific plan coverage practices: results of a focus group. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Dandappanavar A, Knight J, Campbell C, Popelar B, Jackson J, Reeder G. Factors that influence health plan decision-making in the coverage of biomarker diagnostic tests. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 26th Annual Meeting & Expo; April 1-4, 2014; Tampa, FL.

Faria C, Jackson J, Lunacek O. A comparison of time to treatment failure in metastatic breast cancer patients receiving therapy with eribulin mesylate, either with or without dosing modifications. Poster presented at: Breast Cancer Coordinated Care 2014; February 20-22, 2014; Washington, DC.


Li Y, Suh KH, Chen W, Wei ZJ, Higuchi K. Patterns in asthma medication treatment in the US. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual European Congress; November 2-6, 2013; Dublin Ireland.

Carlton R. Cost of completing 1 year of treatment with phentermine/topiramate extended release in an overweight and obese population. Poster presented at: Obesity Society Conference; November 11-16, 2013; Atlanta, GA.

Stafkey-Mailey D, Eaddy M. Treatment patterns and costs of patients with gastrointestinal stromal tumor (GIST) receiving first-line imatinib. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Bramley T. Cost-effectiveness of various combinations of human papillomavirus (HPV)-based testing, including genotyping for HPV 16/18, for cervical cancer screening. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Carlton R, Bramley T. Cost analysis model between the cobas BRAF test and Sanger sequencing when treating malignant melanoma based on the presence of V600 mutations. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Denno M, Dandappanavar A, Raju A, Clark R, Campbell C, Regan T, Jackson J, Skodny P. Systematic literature review and meta-analysis of B-cell therapies in systemic lupus erythematosus. Poster presented
at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.


Bramley T, Zagadailov E. The potential cost savings associated with preventing the development of hypertension, diabetes, and dyslipidemia in an overweight and obese population. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting; May 18-22, 2013; New Orleans, LA.

Carlton R, Clark R, Regan T. The burden of secondary cardiovascular disease in commercial and Medicare patients: a managed care perspective. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 25th Annual Meeting and Expo; April 3-5, 2013; San Diego, CA.

Consaul J. Methods to detect adverse drug reactions using automated healthcare databases. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 25th Annual Meeting and Expo; April 3-5, 2013; San Diego, CA.


Jackson J, Chen L, Sail K, Ericson S, Haislip S, Sharpe J, Gilmore J, Saleh M. Monitoring patterns and subsequent outcomes among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community setting. Poster presented at: American Society Hematology Annual Meeting and Exposition; December 7-11, 2012; Atlanta, GA.

Sail K, Chen L, Jackson J, Ericson S, Haislip S, Ibison T, Gilmore J, Saleh M. Treatment patterns among patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) treated with imatinib in a community setting. Poster presented at: American Society Hematology Annual Meeting and Exposition; December 7-11, 2012; Atlanta, GA.


D'Souza A, Bramley T, Carlton R. A conjoint analysis of willingness to pay to avoid metastatic breast cancer side effects. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 6, 2012; Berlin, Germany.

Bramley T, Bruno A. Patterns of treatment failure among patients receiving anticholinergics for overactive bladder (OAB) treated in a managed care setting. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 6, 2012; Berlin, Germany.

McGee N. Healthy technology assessment evidence criteria: what types of evidence should be presented for products used to screen for disease in the United States? Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual European Congress; November 5, 2012; Berlin, Germany.

Meyer K. Discontinuation rates among atypical antipsychotics for schizophrenia: an indirect treatment comparison. Poster presented at: Academy of Managed Care Pharmacy’s (AMCP) 2012 Educational Conference; October 4, 2012; Cincinnati, OH.

Seal B, Sullivan SD, Ramsey SD, Asche CV, Shermock K, Sarma S, Farrelly E, Eaddy M. Comparing the management and cost of hospitalized prostate cancer patients with and without bone metastases. Poster presented at: Multinational Association of Supportive Cancer Care (MASCC) International Symposium on Supportive Cancer Care; June 28-30, 2012; New York City, NY.


Seal B, Asche C, Puto K, Allen P. Patient-reported outcomes (PROs) and tolerability of therapeutic agents in patients with metastatic prostate cancer (MPC): a systematic literature review. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; June 2-6, 2012; Washington, DC.


Shah M. Outcomes after initiation of fluticasone propionate-salmeterol combination versus anticholinergics in patients with moderate exacerbations of COPD. Poster presented at: Academy of Managed Care Pharmacy’s (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Shah M. Cost-effectiveness of select first-line chemotherapy regimens in the treatment of nonsquamous non-small cell lung cancer patients in the outpatient setting. Poster presented at: Academy of Managed Care Pharmacy’s (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Shah M. Disease-specific costs and resource utilization associated with the initiation of insulin therapy within a type II diabetes mellitus population. Poster presented at: Academy of Managed Care Pharmacy’s (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.

Eaddy M. Evaluating the inpatient hospitalization costs of treating prostate cancer patients. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; June 2-6, 2012; Washington, DC.
Eaddy M. Comparing the use and cost of radiopharmaceuticals in prostate cancer patients with and without bone metastasis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 17th Annual International Meeting; June 2-6, 2012; Washington, DC.

Lennert B. Anticoagulants for stroke prophylaxis in a commercially insured atrial fibrillation population. Poster presented at: Academy of Managed Care Pharmacy’s (AMCP) 24th Annual Meeting & Expo; April 18-20, 2012; San Francisco, CA.


Foran J. Treatment of higher-risk myelodysplastic syndrome (MDS) by American hematology-oncology providers (AHOPs): changes in 1st-line treatment preferences over time in relation to cytogenetics & survival data from randomized studies. Poster presented at: 2011 Annual Meeting of the American Society of Hematology; December 12, 2011; San Diego, CA.


Lalla D, McLaughlin T, Brammer M, Bramley T, Bare A, Carlton R. Willingness to pay for a reduction in risk of treatment side effects in patients with metastatic breast cancer. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Boswell KA, Wang J, Shah MV, Aapro VS. Disease burden and treatment outcomes in second-line therapy of patients with estrogen-receptor positive (ER+) advanced breast cancer: a review of the literature. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual European Congress; November 5-8, 2011; Madrid, Spain.

Polonsky W, Rosenstock J, Gilmore A, Wei W, Chaudhari S, Riddle M. Patient reported outcomes using twice-daily insulin aspart premixed vs insulin glargine plus 1 prandial insulin glulisine or stepwise addition of glulisine to glargine in type 2 diabetes uncontrolled with oral agents. Poster presented at: American Diabetes Association 70th Scientific Sessions Abstract; June 24-28, 2011; San Diego, CA.


Brixner D, Eaddy M, Parkinson J. Applications in using large databases. Xcenda’s short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.
Lawrence C, Roy A, Harikrishnan V, Uy S, Dabbous OH. The association between self-perceived cognitive difficulties and level of depression among employees with current depression. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.


O'Day K, McLaughlin T, Bramley T. Is it time to eliminate the ICER? Using net benefits to report the results of deterministic cost-effectiveness analyses. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.


Gerson LB, Balu S, McLaughlin T, Lunacek O, Jackson J. Examination of resource utilization patterns across subgroups of gastroesophageal reflux disease patients. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Jain G, Roy A, Harikrishnan V, Yu S, Dabbous OH. Association between work productivity and severity of depression among full-time employees as measured by the WPAI & HPQ. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.

Carlton R, Regan T, Rice G. Lower daily average consumption and greater prescription cost savings of armodafinil compared with modafinil: a 12-Month Retrospective Database Analysis. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 16th Annual International Meeting; May 21-25, 2011; Baltimore, MD.


Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Impact of 5-HT3 receptor antagonist selection within triple antiemetic regimes on the risk of uncontrolled chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. Poster presented at: Hematology/Oncology Pharmacy Association 7th Annual Conference; March 23-26, 2011; Salt Lake City, UT.

emetogenic chemotherapy. Poster presented at: Hematology/Oncology Pharmacy Association 7th Annual Conference; March 23-26, 2011; Salt Lake City, UT.


Yu E, Gilmore J, Gilmore AS, Lunacek O, Yim Y, Haislip S, Feinberg S. Patient reported symptoms and treatment patterns of chemotherapy (chemo) and VEGFR/EGFR antibody therapies for the treatment of metastatic colorectal cancer in a US-community oncology setting. Poster presented at: European Society for Medical Oncology (ESMO) Congress; October 8-12, 2010; Milan, Italy.


Ejzykowicz F, Regan T, Gratz-Levenson G. Chronic heart failure: adherence to guidelines by physicians and adherence to therapy by patients in metropolitan vs non-metropolitan areas. Poster presented at: Academy of Managed Care Pharmacy’s (AMCP) 2010 Educational Conference; October 13-15, 2010; St. Louis, MO.


Willey J, Lemke KE, Williams ME, Green MR, Lonial S. Does the magnitude of response to initial induction therapy impact plans for immediate autologous stem cell transplant (ASCT) consolidation in the transplant-eligible patient with a new diagnosis of multiple myeloma (MM)? Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, IL.


Crawford ED, Moul JW, Pettaway C, Sutton S, Poston S, Kruep E. Using prostate-specific antigen threshold to identify increased 4-year risk of prostate cancer. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2010; Chicago, IL.

Brixner D, Eaddy M, Parkinson J. Real-world data methods: applications in using large retrospective databases. Xcenda’s short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.
O’Day K, Meissner B, Bramley T. Ruling out extendedly dominated options in excel using an ICER matrix. Xcenda’s Short Course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.


Rice G, Carlton R, Regan T. The Financial impact of a Daily Average Consumption (DACON) analysis in a US Pharmacy Benefit Management (PBM) company. Xcenda’s short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.

Dhamane AD, Martin B, Brixner D, Hudson TJ, Said Q. Assessment of metabolic monitoring of patients prescribed second-generation antipsychotics (SGAs) using electronic medical record (EMR) data. Xcenda’s short course. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting; May 15-19, 2010; Atlanta, GA.


2002–2007


Vargo J, Bramley T, Meyer K, Nightengale B. Practice efficiency for colonoscopy can be improved by utilizing a sedation agent with a recovery profile that is superior to meperidine and midazolam: results of a Monte Carlo cost simulation model. Poster presented at: Digestive Disease Week (DDW); May 14-19, 2005; Chicago, IL.

Katon WJ, Cantrell CR, Sokol MC, Gdovin JM, Chiao E. Impact of increased antidepressant adherence on comorbid medication use and economic outcomes. Poster presented at: Society of General Internal Medicine (SGIM) Annual Meeting; May 11-14, 2005; New Orleans, LA.

Kaliner M, Crivera C, Szwarcberg J, Bramley T, Chiao E. Physician responses to oropharyngeal adverse events caused by inhaled corticosteroids in adults with asthma. Poster presented at: American Academy of Allergy, Asthma & Immunology (AAAAI) 61st Annual Meeting; March 18-22, 2005; San Antonio, TX.


Rosenfeld WE, Bramley TJ, Meyer K. Patient compliance with topiramate vs. other antiepileptic drugs: a claims database analysis. Poster presented at: American Epilepsy Society; December 3-8, 2004; New Orleans, LA.

Patric K, Stickles J, Bridges E, Turpin R, Jackson J. Disease management under the microscope: a demonstration and comprehensive evaluation of diabetes disease management in a Medicaid population enrolled in a network model managed care organization. Poster presented at: Disease Management Association of America (DMAA) 6th Annual Disease Management Leadership Forum (DMLF); October 20-23, 2004; Orlando, FL.

Grant D, Frieson S, Bridges E, Turpin R, Jackson J. Disease management under the microscope: a demonstration and comprehensive evaluation of a diabetes disease management program in a Medicaid program. Poster presented at: Disease Management Association of America (DMAA) 6th Annual Disease Management Leadership Forum (DMLF); October 20-23, 2004; Orlando, FL.

Frankum LE, Nightengale BS, Russo CL, Sarnes MW. Pharmacoeconomic analysis of antimycotic agents in the treatment of onychomycosis. Poster presented at: Academy of Managed Care Pharmacy (AMCP); April 2, 2004; San Francisco, CA.

Sarnes MW, Eaddy MT, Hill L, Mauch R, Regan T. The Medication Use Evaluation (MUE) software: a depression/anxiety quality improvement tool for managed care. Poster presented at: Academy of Managed Care Pharmacy (AMCP); April 2, 2004; San Francisco, CA.

Regan T, Lennert B, Eaddy M. Incorporating compliance and persistency outcomes into disease management: the national depression/anxiety managed care database study. Poster presented at: Disease Management Association of America (DMAA), Fifth Annual Disease Management Leadership Forum; October 12-15, 2003; Chicago, IL.


Sheehan D, Eaddy M, Sullivan L. Evaluating the economic consequences of SSRI drop-outs in depression. Poster presented at: International Society of Pharmacoeconomics and Outcomes Research (ISPOR); May 2003; Crystal City, VA.


Jackson JH, Farrelly EW, Frechette A, Lennert B, Jhaveri V, Frech F. Determinants of uncontrolled blood pressure in a hypertensive population. Poster presented at: American Heart Association (AHA) 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13, 2002; Washington, DC.

Jackson JH, Farrelly E, Ziska D, Lennert B, Mullany L, Frech F, Hibler S. Heart Failure therapies within managed care. Poster presented at: American Heart Association (AHA) 4th Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; October 13, 2002; Washington, DC.

Jackson JH, Farrelly E, Frechette A. Clinical and economic advantages of fixed-dose combination therapies for treatment of hypertension. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 2002 Educational Conference; October 11, 2002; Washington, DC.


Jackson JH, Farrelly E, Ziska D, Frech F, Hibler S. Heart failure therapies within managed care. Poster presented at: 6th Annual Scientific Meeting of the Heart Failure Society of America; September 23, 2002; Boca Raton, FL.

Maue SK, Godly P. Assessing the prescription burden of hypertensive diabetes patients within managed care plans. Poster presented at: American Diabetes Association (ADA) 62nd Annual Meeting and Scientific Sessions; June 14-18, 2002; San Francisco, CA.


Jackson JH, Maue SK, Godly P. Prevalence of elevated systolic blood pressure in the U.S. Poster presented at: American Heart Association’s Asia Pacific Scientific Forum; April 23-26, 2002; Honolulu, HI.


Jackson JH, Farrelly E, Godly P. Economic impact of fixed-dose combination therapies for treatment of hypertension. Poster presented at: Academy of Managed Care Pharmacy (AMCP) 14th Annual Meeting and Showcase; April 3-6, 2002; Salt Lake City, UT.
Nightengale, BS. The disease burden and cost of illness related to VRI. Poster presented at: Symposium held during Academy of Managed Care Pharmacy (AMCP) Educational Conference: Managing the Cold War: Costs and Complications of Respiratory Illness; October 19, 2001; Dallas, TX.

Godley PJ, Nikam PT, Yokoyama KK, Maue SK, Woodward BW. Blood pressure control within the Scott and White health plan through primary care provider-focused interventions. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Mid-Year Clinical Meeting; December 3-7, 2001; New Orleans, LA.

Maue SK, Farrelly EW, Frech F. The need for improved blood pressure control within the diabetic hypertensive population. Poster presented at: The President’s Poster Reception at American Diabetes Association (ADA) 61st Scientific Sessions; June 22-26, 2001; Philadelphia, PA.


Lennert B, Maves T, Maue SK, Jackson JH. Identifying opportunities to improve clinical outcomes in hypertension: collaboration between pharmacy and quality improvement departments at touchpoint. Poster presented at: 2001 Pharmacy Society of Wisconsin (PSW) Educational Conference; April 26-27, 2001; Madison, WI.

Maue SK, Lennert B, Godley PJ, Berney S. Assessing quality improvement in hypertension care to meet HEDIS 2000 standards. Poster presented at: 13th Annual Meeting & Showcase of the Academy of Managed Care Pharmacy (AMCP); April 18-21, 2001; Tampa, FL.

Nightengale BS, Maue SK, Farrelly EW, Frech F. Identifying hypertension patients for quality improvement: is HEDIS enough? Poster presented at: 13th Annual Meeting & Showcase of the Academy of Managed Care Pharmacy (AMCP); April 18-21, 2001; Tampa, FL.

Maue SK, Farrelly E. Quality improvement opportunities for hypertension care in a managed care setting. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Mid-Year Clinical Meeting; December 3-7, 2000; Las Vegas, NV.

Pham Hoa, Godley PJ, Rohack J, Maue SK. Quality of hypertension care among diabetics in a managed care setting: scope for improvement. Poster presented at: American Society of Health-Systems Pharmacists (ASHP) Mid-Year Clinical Meeting; December 3-7, 2000; Las Vegas, NV.


Maue SK, Gillis CT, Frech FH, Doan Q, Farrelly EW. Identifying opportunities to improve clinical outcomes for hypertensive patients with diabetes in a managed care setting. Poster presented at: American Society of Hypertension (ASH) 15th Scientific Meeting; May 16-20, 2000; New York, NY.


Fraser M, Mofsen R, Kernodle SJ. A quality improvement initiative for patients with dementia. Poster presented at: American Medical Directors Association (AMDA) Annual Meeting; March 4-7, 1999; Orlando, FL.

Rapp KL, Collette A, Mauch RP, Floyd KM. A prescription for balancing quality and cost in the changing reimbursement environment. Poster presented at: American Medical Directors Association (AMDA) Meeting; March 4-7, 1999; Orlando, FL.


Description of a health outcomes management program in a long term care population. Poster presented at: American Society of Consultant Pharmacist (ASCP) 28th Annual Meeting and Exhibition; November 15, 1997; Philadelphia, PA.


Mauch RM, Floyd KM. Health outcomes management program. Poster presented at: American Medical Directors Association (AMDA) Meeting; February 15, 1997; Phoenix, AZ.

Relationship of consultant type and prescription utilization in Florida long term care facilities. Poster presented at: 24th Annual Meeting and Exposition of the American Society of Consultant Pharmacists (ASCP); November 12, 1993; New Orleans, LA.